You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 201771 - 201780 of 207725 results
  1. Development and Commercialization of an Innovative Rapid HIV-1 Incidence Assay

    SBC: SEDIA BIOSCIENCES CORPORATION            Topic: NIAID

    DESCRIPTION (provided by applicant): The objective of this project is to develop a commercially viable point of care Rapid HIV-1 Incidence Assay and establish its suitability for determination of recency of HIV-1 infection in whole blood, plasma, serum specimens for epidemiological, research and surveillance purposes. It is further intended to determine the feasibility of the application of the as ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  2. Endotoxin Neutralization as a Biomonitor for HIV Disease Progression

    SBC: BIODTECH, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): Endotoxin neutralization in human plasma is an excellent indicator of chronic immune activation, which is the most accurate predictor of mortality in HIV. Recently we developed an assay using endotoxin neutralization asan indicator of bacterial translocation. This assay is accurate in discriminating control patients from those with inflammatory bowel disease in ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  3. A sensitive, low-cost, fluorescence assay for determination of HIV p24 in infants

    SBC: SONG DIAGNOSTIC RESEARCH LLC            Topic: NIAID

    DESCRIPTION (provided by applicant): Each year, 1.5 million children are born to mothers living with HIV resulting in vertical transmission of HIV to newborns in 350,000 cases. Early testing followed by prompt anti-retroviral therapy (ART) is known to savelives, yet lack of point-of-care (POC) tests for infants results in delays or absence of therapy. Our approach will provide a low-cost yet quant ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  4. Preclinical Studies of PG70 LEAPS Peptide Vaccines for Rheumatoid Arthritis

    SBC: CEL-SCI CORPORATION            Topic: NIAMS

    DESCRIPTION (provided by applicant): Currently, FDA-licensed pharmaceuticals used to treat rheumatoid arthritis (RA) focus largely on alleviation of symptoms, either through pain management, general immunosuppression, or by antagonizing cytokines such as TNF-?. Despite recent advances in biologic therapies, these treatments do not address the underlying autoimmune condition. Ligand epitope antigen ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. Pre-Operative Assessment of Fusion-Related Bone Failure

    SBC: O.N. DIAGNOSTICS, LLC            Topic: NIAMS

    DESCRIPTION (provided by applicant): With over 400,000 patients undergoing spine fusion surgery each year, many of whom have low bone density because of their advanced age, it is now clear that failure of the bone after a fusion procedure is a serious andincreasingly common problem. This negative outcome of the primary fusion surgery requires the patient have a second surgery, and arises because ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. An antimicrobial-eluting bioresorbable bone filler for orthopaedic application

    SBC: CarMell Therapeutics Corporation            Topic: NIAMS

    DESCRIPTION (provided by applicant): The long-term goal of Carmell Therapeutics for this proposal is to develop a blood plasma-based biomaterial bone filler product that will elute antimicrobials to inhibit infection. Bacterial contamination is present perioperatively in 48-68% o all open wounds and 100% of severe open injuries. Per year in the U.S. ~ 123,000 open tibia fractures are contaminated, ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. Design and synthesis of bone-selective osteogenic oxysterol-bisphosphonate analog

    SBC: Max Biopharma, Inc.            Topic: NIAMS

    DESCRIPTION (provided by applicant): Osteoporosis affects 10 million Americans and another 34 million are osteopenic and at risk for developing osteoporosis. Bone fractures, the most important complication of osteoporosis, cause substantial morbidity andmortality in the aging population as well as significant socio-economic cost. Since the 1960's, bisphosphonate drug therapy has produced mod ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. Development of TAK1 Compounds for Neonatal Onset Multisystem Inflammatory Disease

    SBC: CONFLUENCE LIFE SCIENCES, INC.            Topic: NIAMS

    DESCRIPTION (provided by applicant): Cryopyrin-associated periodic syndromes (CAPS) are a family of rare autoinflammatory diseases of which neonatal-onset multisystem inflammatory disease (NOMID) is the most severe phenotype. NOMID is characterized by NLRP3 activating mutations resulting in excessive interleukin- 1?IL-1?and IL-18 production associated with recurrent fever, rash, skeletal lesions, ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Novel Therapy for Tumor-induced Osteomalacia

    SBC: Panorama Research Incorporated            Topic: NIAMS

    DESCRIPTION (provided by applicant): Tumor-induced osteomalacia (TIO, or oncogenic osteomalacia) is an insidious, progressive, paraneoplastic disorder of abnormal phosphate and vitamin D metabolism caused by excessive fibroblast growth factor 23 (FGF23).Due to a lack of appreciation of the existence of this disease, as well as a typically slow onset of symptoms, the prevalence of TIO is most like ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. A Novel Immunotolerizing Therapy for Autoimmune Vitiligo

    SBC: RADIKAL THERAPEUTICS, INC.            Topic: NIAMS

    DESCRIPTION (provided by applicant): Radikal Therapeutics (RTX) is pioneering a novel therapy to restore immune tolerance and arrest progressive depigmentation in vitiligo. At Loyola University (LUC), a variant to inducible Heat Shock Protein 70 was developed with remarkable potential for the prevention and treatment of autoimmune vitiligo. Carrying only a single amino acid modification to the pro ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government